
Zacks Report Maintains $25 Valuation for Soligenix Despite Market's Muted Response to Clinical Trial Progress
A Zacks Small-Cap Research report maintains a $25 per share valuation for Soligenix based on encouraging clinical trial data for its cutaneous T-cell lymphoma treatment, highlighting a disconnect between strong clinical progress and investor response.
Read full story























